Compare · MRK vs UPC
MRK vs UPC
Side-by-side comparison of Merck & Company Inc. (MRK) and Universe Pharmaceuticals Inc. (UPC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRK and UPC operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- MRK is the larger of the two at $281.24B, about 147159.1x UPC ($1.9M).
- Over the past year, MRK is up 44.0% and UPC is down 29.0% - MRK leads by 73.0 points.
- MRK has hit the wire 25 times in the past 4 weeks while UPC has been quiet.
- MRK has more recent analyst coverage (25 ratings vs 0 for UPC).
- Company
- Merck & Company Inc.
- Universe Pharmaceuticals Inc.
- Price
- $113.89-1.41%
- $2.81-4.42%
- Market cap
- $281.24B
- $1.9M
- 1M return
- -0.32%
- -12.46%
- 1Y return
- +43.97%
- -29.04%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 25
- 0
- Recent ratings
- 25
- 0
Merck & Company Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Universe Pharmaceuticals Inc.
Universe Pharmaceuticals INC, a pharmaceutical company, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It offers products for the treatment and relief for common chronic health conditions in the elderly for the physical wellness and longevity; and cold and flu medications. The company also distributes and sells third-party producers, including biomedical drugs, medical instruments, traditional Chinese medicine pieces products, and dietary supplements. Its customers include pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was incorporated in 2019 and is based in Ji'an, China. Universe Pharmaceuticals INC operates as a subsidiary of Sununion Holding Group Limited.
Latest MRK
- U.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2 through 17 at Increased Risk for Pneumococcal Disease
- Study Reveals Dog Owners and Veterinarians See Challenges in Treating Allergic Skin Disease, Highlighting a Need for a Targeted Rapid Onset Treatment for Dogs of All Ages
- Merck Animal Health to Acquire TARGAN
- Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
- Apotex launches sitagliptin tablets and sitagliptin and metformin hydrochloride tablets, eligible for 180-day shared exclusivity
- SEC Form 4 filed by Director Warden Kathy J
- SEC Form 4 filed by Director Karsanbhai Surendralal Lanca
- SEC Form 4 filed by Director Coe Mary Ellen
- SEC Form 4 filed by Director Thulin Inge G
- SEC Form 4 filed by Director Seidman Christine E
Latest UPC
- Chief Executive Officer Lai Gang was granted 71,890 units of Class A ordinary shares and was granted 12,610 units of Class B ordinary shares (SEC Form 4)
- SEC Form 6-K filed by Universe Pharmaceuticals Inc.
- SEC Form 6-K filed by Universe Pharmaceuticals Inc.
- SEC Form 3 filed by Universe Pharmaceuticals Inc.
- SEC Form 3 filed by Universe Pharmaceuticals Inc.
- SEC Form 3 filed by Universe Pharmaceuticals Inc.
- SEC Form 3 filed by new insider Yang Lin (Lydia)
- SEC Form 3 filed by new insider Lai Gang
- SEC Form 3 filed by Universe Pharmaceuticals Inc.
- SEC Form 6-K filed by Universe Pharmaceuticals Inc.